Whitehawk Therapeutics (WHWK) Other Non-Current Assets (2016 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Other Non-Current Assets of $1.7 million for Q1 2026, up 23.33% year-over-year from $1.4 million in Q1 2025, and down 7.33% quarter-over-quarter from $1.8 million in Q4 2025.
Whitehawk Therapeutics (WHWK) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Other Non-Current Assets for 11 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 23.33% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 23.33% YoY), while the FY2025 annual figure was $1.8 million, up 29.66% from the prior year.
- Other Non-Current Assets eased to $1.7 million in Q1 2026 per WHWK's latest filing, from $1.8 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.3 million in Q1 2022 and bottomed at $1.4 million in Q1 2025.
- Historically, Other Non-Current Assets has averaged $1.9 million across 5 years, with a median of $1.9 million in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 11585.0% — and 2024, when it retreated 25.03%.
- Whitehawk Therapeutics' Other Non-Current Assets stood at $2.2 million in 2022, then declined by 14.33% to $1.9 million in 2023, then declined by 25.03% to $1.4 million in 2024, then rose by 29.66% to $1.8 million in 2025, then retreated by 7.33% to $1.7 million in 2026.
- Business Quant data shows WHWK's Other Non-Current Assets at $1.7 million in Q1 2026, $1.8 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | 1.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Mn |
| Mar 31, 2026 | 1.68 Mn |
| Dec 31, 2025 | 1.81 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 1.36 Mn |
| Dec 31, 2024 | 1.40 Mn |
| Sep 30, 2024 | 1.52 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.74 Mn |
| Dec 31, 2023 | 1.87 Mn |
| Sep 30, 2023 | 1.91 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 2.21 Mn |
| Jun 30, 2022 | 2.29 Mn |
| Mar 31, 2022 | 2.34 Mn |
| Dec 31, 2021 | 2.21 Mn |
| Sep 30, 2021 | 2.26 Mn |